Brief: Pfizer Says Padcev Plus Keytruda Improves Survival for Certain Bladder Cancer Patients Pre/Post-Surgery
12/08/2025 10:30
Aug 12 (Reuters) - Pfizer: PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR CERTAIN PATIENTS WITH BLADDER CANCER WHEN GIVEN BEFORE & AFTER SURGERY PFIZER: ADDITIONAL SECONDARY ENDPOINT OF PATHOLOGIC COMPLETE RESPONSE RATE MET PFIZER: PHASE 3 EV-303 CLINICAL TRIAL RESULTS TO BE DISCUSSED WITH GLOBAL HEALTH AUTHORITIES FOR POTENTIAL GLOBAL REGULATORY FILINGS PFIZER: SAFETY PROFILES FOR PADCEV PLUS KEYTRUDA & KEYTRUDA MONOTHERAPY CONSISTENT WITH KNOWN PROFILES OF EACH TREATMENT REGIMEN Source text: [ID:] Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)